(NASDAQ: PETQ) Petiq's forecast annual revenue growth rate of 4.69% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.26%.
Petiq's revenue in 2024 is $1,134,329,000.On average, 3 Wall Street analysts forecast PETQ's revenue for 2024 to be $34,476,408,201, with the lowest PETQ revenue forecast at $34,036,908,009, and the highest PETQ revenue forecast at $34,724,280,811. On average, 3 Wall Street analysts forecast PETQ's revenue for 2025 to be $36,372,780,104, with the lowest PETQ revenue forecast at $35,683,614,156, and the highest PETQ revenue forecast at $36,726,627,669.
In 2026, PETQ is forecast to generate $39,269,907,036 in revenue, with the lowest revenue forecast at $39,269,907,036 and the highest revenue forecast at $39,269,907,036.